达可替尼与吉非替尼一线治疗EGFR突变阳性晚期非小细胞肺癌患者的疗效
Efficacy of Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR Mutation Positive Non-Small Cell Lung Cancer
达可替尼与吉非替尼一线治疗EGFR突变阳性晚期非小细胞肺癌患者的疗效 |
|
评价者：邬麟 |
Efficacy of Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR Mutation Positive Non-Small Cell Lung Cancer |
| |